3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Multiple Myeloma
5
Breast Neoplasms
5
Prostatic Neoplasms
4
Hematologic Neoplasms
4
Carcinoma, Renal Cell
4
Urinary Bladder Neoplasms
3
Neuroendocrine Tumors
3
Neoplasm Metastasis
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Head and Neck Neoplasms
3
Urothelial Cancer
2
Thyroid Neoplasms
2
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neurofibromatosis 1
2
Neurofibroma, Plexiform
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Adenoma, Islet Cell
2
von Hippel-Lindau Disease
1
Uterine Neoplasms
1
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Salivary Gland Neoplasms
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA